1. Home
  2. STTK

as 09-12-2025 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Founded: 2016 Country:
United States
United States
Employees: N/A City: AUSTIN
Market Cap: 83.8M IPO Year: 2020
Target Price: $2.67 AVG Volume (30 days): 1.6M
Analyst Decision: Hold Number of Analysts: 6
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.21 EPS Growth: N/A
52 Week Low/High: $0.69 - $3.95 Next Earning Date: 08-14-2025
Revenue: $2,997,000 Revenue Growth: -27.33%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

STTK Daily Stock ML Predictions

Stock Insider Trading Activity of Shattuck Labs Inc. (STTK)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
ORBIMED ADVISORS LLC STTK Director Aug 25 '25 Buy $0.87 6,306,127 $5,471,826.40 5,255,106
Ashiya Mona STTK Director Aug 25 '25 Buy $0.87 6,306,127 $5,471,826.40 5,255,106

Share on Social Networks: